EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

[Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate–severe psoriasis with certolizumab pegol

Andrés Navarro Ruiz, Fernando Toledo Alberola, Susana Aceituno, Grupo ARCODERM

Farmacia Hospitalaria · 2024

DOI: 10.1016/j.farma.2023.11.004 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Farmacia Hospitalaria, 2024. Verfasst von Andrés Navarro Ruiz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia del Hospital General Universitario de Elche, Alicante, Spain. Electronic address: navarro_and@gva.es. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: UCB Pharma SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To provide evidence of the effectiveness of certolizumab pegol (CZP) in real clinical practice in adult patients with moderate-to-severe plaque psoriasis (PsO) in the context of a risk-sharing agreement (RSA). METHODS: Retrospective observational study based on variables collected in the RSA for treatment with CZP of adult patients with moderate-severe plaque PsO. Ten Spanish hospitals where the RSA was implemented participated. The percentage of patients who achieved the target clinical response of the RSA at the follow-up visit (week 16) was evaluated: absolute Psoriasis Area and Severity Index (PASI) value ≤3 for biologic naïve population, and ≤5 in case of previous failure to a single biologic drug. In addition, the improvement in the scores of other scales included in the study was analysed: Body Surface Area (BSA), Dermatology Life Quality Index (DLQI), Physician's Global Assessment (PGA), and Nail Psoriasis Severity Index (NAPSI). A descriptive analysis was performed for the total population and by patient subgroups (naive vs. non-naive to biologic, male vs. female, and with vs. without discontinuation). RESULTS: Sixty-six patients were included, 12 men and 54 women. 90.9% achieved the target clinical response, with a mean reduction of 8 (-78.4%) absolute PASI points. Improvement was observed in BSA, PGA, NAPSI, and DLQI, with a reduction of 11.3 (-80.6%), 1.9 (-65.5%), 3.3 (-30.7%), and 9.0 (-66.4%) absolute value points, respectively. Despite not achieving the therapeutic target set in the RSA in 6 patients (9%) (the cost of the drug was assumed by the laboratory), only 2 (3%) discontinued treatment. CONCLUSION: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analysed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsAdultFemaleHumansMaleCertolizumab PegolTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

Acuerdos de riesgo compartidoCertolizumab pegolEfectividadEffectivenessHealth outcomesPsoriasisResultados en saludRisk-sharing agreementcertolizumab pegol

Substanzen

Certolizumab PegolBiological Products

Autor:innen und Institutionen

  • Servicio de Farmacia del Hospital General Universitario de Elche, Alicante, Spain. Electronic address: navarro_and@gva.es.
  • Servicio de Dermatología del Hospital General Universitario de Elche, Alicante, Spain.
  • Outcomes'10, SLU, Castellón, Spain.

Förderung

  • UCB Pharma SA

Zitieren

APA

Ruiz, A. N., Alberola, F. T., Aceituno, S., & Grupo ARCODERM (2024). [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate–severe psoriasis with certolizumab pegol. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2023.11.004

Vancouver

Ruiz AN, Alberola FT, Aceituno S, Grupo ARCODERM. [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate–severe psoriasis with certolizumab pegol. Farmacia Hospitalaria. 2024. doi:10.1016/j.farma.2023.11.004

BibTeX
@article{Ruiz2024,
  author = {Ruiz, Andrés Navarro and Alberola, Fernando Toledo and Aceituno, Susana and Grupo ARCODERM, Grupo ARCODERM},
  title = {[Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate–severe psoriasis with certolizumab pegol},
  journal = {Farmacia Hospitalaria},
  year = {2024},
  doi = {10.1016/j.farma.2023.11.004}
}
Kostenlos starten →